Show simple item record

dc.contributor.authorde Wit, Mariten
dc.contributor.authorRao, Bhargavien
dc.contributor.authorLassovski, Maryvonneen
dc.contributor.authorOuabo, Adelaideen
dc.contributor.authorBadjo, Coletteen
dc.contributor.authorBousema, Teunen
dc.contributor.authorRoper, Callyen
dc.contributor.authorOkell, Lucyen
dc.contributor.authorPiriou, Erwanen
dc.contributor.authorCibindaen
dc.date.accessioned2018-07-27T12:32:42Z
dc.date.available2018-07-27T12:32:42Z
dc.date.issued2018-07
dc.identifier.urihttp://hdl.handle.net/10144/619222
dc.descriptionResearch Protocolen
dc.description.abstractPrimary Objective: To measure the prevalence of molecular markers of SP resistant malaria in North and South Kivu, DRC. Sulfadoxine/pyrimethamine (SP) forms the backbone of most malaria chemoprevention programmes in high endemicity settings, including intermittent preventative therapy in pregnancy and infants (IPTp and IPTi respectively) as well as seasonal malaria chemoprevention (SMC). P. falciparum parasite resistance to SP threatens recent triumphs preventing malaria infection in the most vulnerable risk groups. WHO guidance is that chemoprevention using SP may not be implemented when prevalence of the dhps K540E gene denoting SP resistance are greater than 50%. Simple, robust polymerase chain reaction (PCR) - based methods for molecular surveillance of resistance to SP have the potential to indicate whether SP-based chemoprevention programmes would be effective in areas where surveillance was conducted, but also to identify early stages of emerging resistance in order to advocate for alternative chemoprevention strategies.A minimum of 750 samples will be collected per province. Three sites per province will provide 250 samples assuming an estimated prevalence of 50% prevalence of dhps K540E gene with 95% confidence and 5% precision. This is also sufficient for robust estimation of the prevalence of dhps 581, an alternative critical marker. This sample size is calculated to estimate regional prevalence, i.e. for both South Kivu and North Kivu, and hence this study requires samples from multiple MSF sites (including from different MSF Operating Centre missions) e.g. Baraka, Kimbi and Lulingu amongst others in South Kivu and Mweso, Rutsuru and Walikale in North Kivu with a minimum total of 750 per province. If estimating specific prevalence in only one limited site, a large sample size would be required.
dc.language.isoenen
dc.rightsThese materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.pngen
dc.subjectSP resistanceen
dc.subjectMolecular Markeren
dc.subjectPrevalence Surveyen
dc.subjectDRCen
dc.titleSURVEY OF PLASMODIUM FALCIPARUM SULFADOXINE/PYRIMETHAMINE (SP) RESISTANCE MARKERS IN MSF PROJECTS IN NORTH AND SOUTH KIVU, DR CONGO Short Title: SP Resistance Molecular Marker Prevalence Survey DRCen
dc.typeOtheren
dc.contributor.departmentMSF-OCAen
refterms.dateFOA2019-02-21T13:46:58Z
html.description.abstractPrimary Objective: To measure the prevalence of molecular markers of SP resistant malaria in North and South Kivu, DRC. Sulfadoxine/pyrimethamine (SP) forms the backbone of most malaria chemoprevention programmes in high endemicity settings, including intermittent preventative therapy in pregnancy and infants (IPTp and IPTi respectively) as well as seasonal malaria chemoprevention (SMC). P. falciparum parasite resistance to SP threatens recent triumphs preventing malaria infection in the most vulnerable risk groups. WHO guidance is that chemoprevention using SP may not be implemented when prevalence of the dhps K540E gene denoting SP resistance are greater than 50%. Simple, robust polymerase chain reaction (PCR) - based methods for molecular surveillance of resistance to SP have the potential to indicate whether SP-based chemoprevention programmes would be effective in areas where surveillance was conducted, but also to identify early stages of emerging resistance in order to advocate for alternative chemoprevention strategies.A minimum of 750 samples will be collected per province. Three sites per province will provide 250 samples assuming an estimated prevalence of 50% prevalence of dhps K540E gene with 95% confidence and 5% precision. This is also sufficient for robust estimation of the prevalence of dhps 581, an alternative critical marker. This sample size is calculated to estimate regional prevalence, i.e. for both South Kivu and North Kivu, and hence this study requires samples from multiple MSF sites (including from different MSF Operating Centre missions) e.g. Baraka, Kimbi and Lulingu amongst others in South Kivu and Mweso, Rutsuru and Walikale in North Kivu with a minimum total of 750 per province. If estimating specific prevalence in only one limited site, a large sample size would be required.


Files in this item

Thumbnail
Name:
SP_protocol_MSF_ERB_changes_ac ...
Size:
759.6Kb
Format:
Microsoft Word 2007
Description:
Research Protocol

This item appears in the following Collection(s)

Show simple item record